Robert S. Landsman

Array ( [id] => 17945761 [patent_doc_number] => 20220332778 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-20 [patent_title] => METHODS FOR TREATING MYELOPROLIFERATIVE DISORDERS [patent_app_type] => utility [patent_app_number] => 17/535100 [patent_app_country] => US [patent_app_date] => 2021-11-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61554 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17535100 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17867118 [patent_doc_number] => 20220289853 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => METHOD OF TREATING OR DELAYING PROGRESSION OF AN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)-RELATED DISORDER BY ADMINISTERING ACTIVATABLE EGFR-BINDING ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/532193 [patent_app_country] => US [patent_app_date] => 2021-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31870 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17532193 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18127981 [patent_doc_number] => 11554177 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-17 [patent_title] => Antibody-drug conjugates targeting human Claudin 18.2 [patent_app_type] => utility [patent_app_number] => 17/530209 [patent_app_country] => US [patent_app_date] => 2021-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 30 [patent_no_of_words] => 22580 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17530209 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19717347 [patent_doc_number] => 12202870 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-21 [patent_title] => Antigen binding molecules comprising a trimeric TNF family ligand and encoding polynucleotides thereof [patent_app_type] => utility [patent_app_number] => 17/455617 [patent_app_country] => US [patent_app_date] => 2021-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 103 [patent_no_of_words] => 67263 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 190 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17455617 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18910373 [patent_doc_number] => 11873343 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-16 [patent_title] => Pharmaceutical formulations comprising anti-RANKL antibodies and an aromatic amino acid comprising a phenyl or an indole [patent_app_type] => utility [patent_app_number] => 17/529794 [patent_app_country] => US [patent_app_date] => 2021-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 37 [patent_no_of_words] => 31600 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17529794 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17613023 [patent_doc_number] => 20220155303 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => USE OF TCTP AS BIOMARKER FOR PREDICTING EFFICACY, PROGNOSIS OF IMMUNOTHERAPY OR RESISTANCE THERETO, AND TARGET OF IMMUNOTHERAPY FOR ENHANCING EFFICACY [patent_app_type] => utility [patent_app_number] => 17/528578 [patent_app_country] => US [patent_app_date] => 2021-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12117 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17528578 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18916737 [patent_doc_number] => 11879007 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-23 [patent_title] => Nucleic acids encoding anti-gliadin antibodies [patent_app_type] => utility [patent_app_number] => 17/528025 [patent_app_country] => US [patent_app_date] => 2021-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 12968 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 129 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17528025 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20218690 [patent_doc_number] => 20250281621 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-09-11 [patent_title] => GPC3 APTAMERS AND VARIANTS AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/252763 [patent_app_country] => US [patent_app_date] => 2021-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12081 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18252763 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17642007 [patent_doc_number] => 20220169745 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => ANTIBODIES AND ASSAYS FOR DETECTION OF FOLATE RECEPTOR 1 [patent_app_type] => utility [patent_app_number] => 17/523126 [patent_app_country] => US [patent_app_date] => 2021-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41505 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17523126 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19675955 [patent_doc_number] => 12187805 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-07 [patent_title] => Type-II VNAR polypeptides which bind human TfR-1, encoding nucleic acids thereof and method of use thereof [patent_app_type] => utility [patent_app_number] => 18/033600 [patent_app_country] => US [patent_app_date] => 2021-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 15 [patent_no_of_words] => 20459 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18033600 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17508843 [patent_doc_number] => 20220101946 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => DEVELOPING CLASSIFIERS FOR STRATIFYING PATIENTS [patent_app_type] => utility [patent_app_number] => 17/517521 [patent_app_country] => US [patent_app_date] => 2021-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35577 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17517521 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18815997 [patent_doc_number] => 20230390336 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-07 [patent_title] => CHIMERIC ANTIGEN RECEPTOR TARGETING CD7 AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/034177 [patent_app_country] => US [patent_app_date] => 2021-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15528 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18034177 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17611572 [patent_doc_number] => 20220153851 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => Antibodies that Bind Colony Stimulating Factor 1 Receptor (CSF1R) [patent_app_type] => utility [patent_app_number] => 17/513109 [patent_app_country] => US [patent_app_date] => 2021-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22388 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17513109 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18817552 [patent_doc_number] => 20230391892 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-07 [patent_title] => BIFUNCTIONAL ANTAGONISTS OF TUMOR NECROSIS FACTOR ALPHA AND TRANSFORMING GROWTH FACTOR BETA AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/033337 [patent_app_country] => US [patent_app_date] => 2021-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27957 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18033337 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19258042 [patent_doc_number] => 12018086 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-25 [patent_title] => Kit comprising contiguous nucleobases, including position 76, of RS5745994 [patent_app_type] => utility [patent_app_number] => 17/508128 [patent_app_country] => US [patent_app_date] => 2021-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 4 [patent_no_of_words] => 30249 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17508128 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18902735 [patent_doc_number] => 20240018220 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-18 [patent_title] => METHODS OF TREATING PATIENTS HAVING COMPLEMENT DISORDERS USING ANTI-C5 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/032959 [patent_app_country] => US [patent_app_date] => 2021-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26122 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18032959 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17386002 [patent_doc_number] => 20220033854 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => SYSTEMS AND METHODS FOR EXPRESSING PROTEINS [patent_app_type] => utility [patent_app_number] => 17/503656 [patent_app_country] => US [patent_app_date] => 2021-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7391 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17503656 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18806948 [patent_doc_number] => 20230381281 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-30 [patent_title] => PHARMACEUTICAL COMPOSITION COMPRISING GLUCAGON/GLP-1/GIP TRIPLE AGONIST OR LONG-ACTING CONJUGATE THEREOF FOR PREVENTING OR TREATING LUPUS-RELATED DISEASES [patent_app_type] => utility [patent_app_number] => 18/031940 [patent_app_country] => US [patent_app_date] => 2021-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16914 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18031940 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18817518 [patent_doc_number] => 20230391858 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-07 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING BLOOD DISORDERS [patent_app_type] => utility [patent_app_number] => 18/032084 [patent_app_country] => US [patent_app_date] => 2021-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44342 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -74 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18032084 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20083779 [patent_doc_number] => 20250213715 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-03 [patent_title] => ANTI-CSPG4 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 18/247628 [patent_app_country] => US [patent_app_date] => 2021-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29218 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18247628 [rel_patent_id] =>[rel_patent_doc_number] =>)